Skip to main content
Equibles
SPRB logo

SPRB · Spruce Biosciences, Inc.

Track SPRB — free

Use SPRB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SPRB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$44.36 -0.79 (-1.75%)
Russell 2000 member Rebalance outlook locked
Market Cap
$127.58M
Shares
2.87M
Volume · Oct 26 44.33K Avg daily vol (3M) 80.17K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$45.15 Open$45.80 Day$43.34–46.10 52W close$38.98–133.24 Avg vol 30d87K Short int432K · 15.0% float · 4.5d Short vol56% Last earningsNov 12, 2024 DataAug 2025–Oct 2026 Filing10-Q · Aug 12

Raw chart and full-history price indicators begin at the captured split on Aug 7, 2025; bars on opposite sides are not compared.

Up next

Latest filing: 10-Q
filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$51.35M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$89.20M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+311.3%
Year over year · more shares
Price change (1Y)
-65.2%
Trailing year
Short interest
15.0%
Latest settlement · 4.5 days to cover
View all 122 metrics

Quarterly results

Revenue Net income Net loss
▲1.9% $2.00M −$11.62M '24 Q1 ▼25.6% $1.61M −$9.18M '24 Q2 ▼80.4% $602,000 −$8.67M '24 Q3 ▼75.9% $697,000 −$23.56M '24 Q4* ▼100% $0 −$14.04M '25 Q1 ▼100% $0 −$2.07M '25 Q2 ▼100% $0 −$8.21M '25 Q3 LATEST ▼100% $0 −$14.65M '25 Q4*

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 19.5 · elevated Equity put/call 0.67
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −20%
below
Price vs 50-day avg −11%
below
RSI (14) 49
neutral
MACD trend Positive
52-week position 7%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −7%
trailing
6-month return −24%
trailing
YTD return −48%
this year
Relative strength −30%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $51 › 200d $57 — 200d above 50d
Institutional flow Accumulating
5 of 64 funds reported for Sep 30 · net +110 sh shares · +3 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
15.02% of float · ▲ +3.7% MoM · 4.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
64 holders — near 3-yr high, broad support
Squeeze score 66
elevated · 0–100
Fundamentals
Fair
Revenue growth −100%
Y/Y
EPS growth +47%
Y/Y
Free cash flow $-33.3M
Balance sheet $48.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 85%
annualized · 1-yr
Max drawdown −71%
past year
ATR 6.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−20% Bearish
Price vs 50-day avg
−11% Bearish
RSI (14)
49 Neutral
MACD trend
Positive Bullish
52-week position
7% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $51 › 200d $57 — 200d above 50d
Institutional flow Accumulating
5 of 64 funds reported for Sep 30 · net +110 sh shares · +3 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
15.02% of float · ▲ +3.7% MoM · 4.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
64 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $39 Now $45 · 7% Range high $133
vs 200-day avg -20% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SPRB
Spruce Biosciences, Inc.
this stock
$127.58M -48.2% -100.0% — 15.0%
VRTX
Vertex Pharmaceuticals Inc
 $130.00B +15.6% +46.2% 29.9 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.88B +4.3% +20.8% 19.9 2.1%
MRNA
Moderna, Inc.
 $79.89B +578.5% +4.3% — 7.7%
CSLLY
Csl Ltd
 $66.42B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
67
% held
69.8%
Reported
5 of 64
Top holder
AIGH Capital Management L…
Held Float
View
Held by Funds
Fund positions
69
View
Short & Settlement
Short Interest Rising
Shares short
431.5K
Days to cover
4.5d
Change
+15.4K sh
View
Short Volume
Short vol %
56%
As of
Oct 23, 2026
Short Total
View
Fails to Deliver
FTD shares
95
Value
$4.5K
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
22.9%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-39.0M
EPS diluted
$-50.83
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Oct 22, 2026
This year
17

Spruce expects to submit its BLA in the fourth quarter, says the Samsung Biologics strike should not affect manufacturing, and projects about 20 new patients per year in the U.S.

View
Proposed Sales
Value
$3.9M
Shares
4.8M
Filed
Mar 18, 2024
View
Exempt Offerings
Offering
$50.0M
Filed
Oct 17, 2025
View
Earnings & Events
Webcasts
Last webcast
Oct 22, 2026
View
Investor Relations
Latest news
Spruce Biosciences to Participate…
Published
Oct 15, 2026
View

Performance

Raw-price comparisons begin at the captured split on Aug 7, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
SPRB +13.9% -7.3% -24.0% -7.1% -48.2%
SPY -0.4% -1.5% +5.8% -0.4% +11.5%
vs SPY +14.3% -5.9% -29.8% -6.7% -59.6%
Key facts CIK 1683553 CUSIP 85209E208 13F (30d) 5 filings 5 filers Visit website Investor relations